Memantin Sandoz

Memantine Hydrochloride, the active ingredient in Memantin Sandoz, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adults, helping to preserve cognition, daily functioning, and behavioral stability across EU markets.

GNH USA supplies Memantin Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution.

Memantin Sandoz, an NMDA receptor antagonist, is employed in the management of Alzheimer’s disease, a neurodegenerative disorder affecting memory and cognition.

Alzheimer’s disease (moderate to severe): improves cognitive function and supports daily activities. Alzheimer’s disease (mild to moderate): may delay symptom progression and aid memory retention. Alzheimer’s disease (behavioral symptoms): can reduce agitation and improve overall patient behavior.

Memantin Sandoz may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reaction (anaphylaxis) - Stevens‑Johnson syndrome - Hallucinations

When prescribing Memantin Sandoz, clinicians should consider several precautionary measures to ensure patient safety.

Renal impairment: adjust dose or monitor renal function. Hepatic disease: use with caution and monitor liver enzymes. History of seizures: evaluate risk before initiating therapy. Concomitant use with other NMDA antagonists: avoid additive neuropsychiatric effects. Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Memantin Sandoz can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined use may increase risk of neuropsychiatric adverse events. - High‑dose quinidine: may elevate memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits of memantine. - Carbamazepine: induces metabolism, potentially reducing memantine levels. - Proton pump inhibitors (e.g., omeprazole): may modestly increase memantine exposure.